Universiteit Twente

Enceladus Pharmaceuticals B.v.

Singapore Health Services Pte Ltd

Universiteit Utrecht Holding B.v.

Laurentia Holding B.v.

Gerrit Storm

Jai Prakash

Josbert Maarten Metselaar

Marca Henriette M Wauben

Peter Van Hoogevest

Chee Wai Wong

Marca Henriette Wauben

Bertrand Marcel Stanislas Czarny

A composition comprising a liposome comprising a first phospholipid comprising a C-C:0 fatty acid and a C-C:0 fatty acid with a c-terminal carboxyl or a carboxaldehyde group; a second phospholipid comprising a C-C:0 fatty acid and a C-C:0 fatty acid and a sterol. The first phospholipid is preferably a phosphatidylcholine. The second phospholipid is preferably HSPC and the sterol is preferably cholesterol. In some embodiments, the molar ratio of the respective ingredients is 2-3:5-6:2-3; preferably 2:6:2; or 3:5:2, respectively. The invention also relates to the use of this composition in the targeting of M2 macrophages.

Liposomes for targeting tumor-associated macrophages

A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.

Composition for treatment of inflammatory disorders

Growing community of inventors

Utrecht, Netherlands

Gerrit Storm